← 產業報告目錄

Protein A Resin Market by Product (Bulk Resin, Lab-scale Columns), Source (Recombinant Protein A), Matrix Type (Agarose-Based Protein A), Application (Monoclonal Antibody Purification, FC-Fusion Protein Purification) & End User - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Machinery & Equipment出版日期 2025-08-27頁數 212報告編號 AST7818

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global protein A resin market is projected to reach USD 2.0 billion by 2030 from USD 1.5 billion in 2025, at a CAGR of 6.5% during the forecast period. Market growth is attributed to increased outsourced services through CDMOs, with major players expanding multi-plant biomanufacturing capacities across developed markets. The global monoclonal antibody (mAb) pipeline is growing, marked by high FDA approvals and new bispecific and antibody-drug conjugate launches. This has helped boost purification requirements among end users, which is expected to increase the market for protein A resin. “Based on product, bulk resins held the largest share of the protein A resin market in 2024.” Based on products, the protein A resin market is divided into bulk resin, pre-packed columns, lab-scale columns, and others. Unlike pre-packed formats, bulk resin is the industry standard for high-volume purification processes in stainless-steel column setups. While it requires in-house packing and validation, bulk resin provides a much lower cost per cycle and per gram of purified monoclonal antibody. It is the preferred choice among end users because of its reusability. Most types can support 50 to over 200 cycles, enabling long-term production runs with minimal resin replacement. This feature directly enhances the economic efficiency and productivity goals of commercial manufacturing. All these factors make bulk resin the favored choice in the end-use industries. “Based on matrix type, the agarose-based protein A resin segment accounted for the largest share during the forecast period.” The protein A resin market is categorized by matrix type into agarose-based, glass/silica-based, and organic polymer-based varieties. Among these, agarose-based protein A resins represent the largest market share. They are known for their improved durability, stronger mechanical properties, and higher capacity to absorb metal dopants at suitable pH levels. Recent developments in agarose-based resins include next-generation products such as Praesto CH1 and DurA Cycle A50, which offer better durability, increased binding capacity, and improved compatibility with complex antibody formats like bispecifics and fragments. These new products feature engineered ligands with enhanced alkaline resistance, enabling longer reuse and better cost efficiency. "Based on applications, the monoclonal antibodies purification segment has acquired the largest share in 2024.” Based on applications, the protein A resin market is divided into mAb purification, Fc-fusion protein purification, and other applications. mAb purification holds the largest share in the protein A resin market mainly because of its established role in large-scale biopharmaceutical manufacturing. mAbs are the most widely produced category of biologic therapeutics, requiring large amounts of protein A resin for the primary capture steps in downstream processing. Protein A resin is preferred due to its Fc region binding specificity and compliance with regulatory standards for product purity and consistency. Moreover, a significant portion of the installed biomanufacturing capacity across pharmaceutical companies and contract manufacturing organizations is dedicated to mAb production, which naturally increases demand for protein A resin in this segment. “Based on end users, the pharmaceutical and biopharmaceutical companies segment accounted for the largest share in 2024.” Pharmaceutical and biopharmaceutical companies account for the major share in the protein A resin market due to their role as the primary manufacturers of therapeutic proteins, particularly monoclonal antibodies (mAbs) and Fc-fusion proteins. These companies operate large-scale production facilities where protein A resin is extensively used in downstream purification processes, requiring significant resin volumes to meet commercial supply needs and regulatory compliance standards. Additionally, in-house manufacturing setups within these organizations prioritize consistent supply chains and quality control, further reinforcing direct procurement of protein A resins rather than relying solely on outsourced partners. This structural reliance on protein A resin for core biologics manufacturing activities positions pharmaceutical and biopharmaceutical companies as the dominant end-user segment in the market. “North America is expected to hold a significant market share in the protein A resin market throughout the forecast period.” The protein A resin market includes five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America held a significant market share for protein A resin. Its dominant position is due to increased manufacturing capacity, focusing on commercial-scale and clinical trial supply production. Investment trends show that US federal and state support promotes domestic biomanufacturing for pandemic preparedness and reducing reliance on international supply chains. Small- to mid-sized biotech firms are increasingly partnering with CDMOs. These factors have helped North America secure the largest market share in 2024. A breakdown of the primary participants referred to for this report is provided below: • By Company Type: Tier 1 (35%), Tier 2 (45%), and Tier 3 (20%) • By Designation: C-level Executives (35%), Directors (25%), and Others (40%) • By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%), and the Middle East & Africa (5%) The key players profiled in the protein A resin market are Danaher Corporation (US), Repligen Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific (US), Agilent Technologies (US), GenScript (China), Bio-Rad Laboratories, Inc. (US), Orochem Technologies Inc. (US), Kaneka Corporation (Japan), Abcam Plc. (UK), Ecolab (US), and Tosoh Biosciences LLC (Japan). Research Coverage The research report analyzes the protein A resin market by product, matrix type, source, application, end user, and region. It explores the factors driving market growth, examines the challenges and opportunities faced by various industries, and presents details on the competitive landscape, including market leaders and small to medium-sized enterprises. Additionally, it estimates the revenue generated by different market segments across five regions and includes a micromarket analysis. Reasons to Buy the Report The report will help market leaders and new entrants by providing accurate revenue estimates for the protein A resin market and subsegments. It will assist stakeholders in understanding the competitive landscape, enabling them to position their businesses more effectively and develop suitable go-to-market strategies. Additionally, the report offers insights into market dynamics, including key drivers, restraints, challenges, and opportunities. This report provides insightful data on the following pointers: • Market Penetration: In-depth coverage of product portfolios offered by the top players in the protein A resin market. • Product Development/Innovation: In-depth coverage of product portfolios offered by the top players in the protein A resin market. • Market Development: Insightful data on profitable developing areas. • Market Diversification: Details about recent developments and advancements in the protein A resin market. • Competitive Assessment: Extensive assessment of the products, growth tactics, revenue projections, and market categories of the top competitors.
目錄 Table of Contents
1 INTRODUCTION 21 1.1 STUDY OBJECTIVES 21 1.2 MARKET DEFINITION 21 1.3 STUDY SCOPE 22 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 22 1.3.2 INCLUSIONS AND EXCLUSIONS 23 1.3.3 YEARS CONSIDERED 23 1.3.4 CURRENCY CONSIDERED 24 1.4 STAKEHOLDERS 24 1.5 SUMMARY OF CHANGES 24 2 RESEARCH METHODOLOGY 25 2.1 RESEARCH DATA 25 2.1.1 SECONDARY RESEARCH 26 2.1.1.1 Key secondary sources 27 2.1.1.2 Key data from secondary sources 28 2.1.1.3 Objectives of secondary research 28 2.1.2 PRIMARY RESEARCH 29 2.1.2.1 Key primary sources 29 2.1.2.2 Key supply and demand-side participants 29 2.1.2.3 Breakdown of primary interviews 30 2.1.2.4 Objectives of primary research 30 2.1.2.5 Key primary insights 31 2.2 MARKET SIZE ESTIMATION 31 2.2.1 BOTTOM-UP APPROACH 32 2.2.1.1 Company revenue estimation 33 2.2.1.2 Customer-based market estimation 33 2.2.1.3 Primary interviews 34 2.2.2 TOP-DOWN APPROACH 34 2.3 GROWTH RATE ASSUMPTIONS 36 2.4 DATA TRIANGULATION 38 2.5 STUDY ASSUMPTIONS 39 2.6 RESEARCH LIMITATIONS 39 2.7 RISK ANALYSIS 39 3 EXECUTIVE SUMMARY 40   4 PREMIUM INSIGHTS 45 4.1 PROTEIN A RESIN MARKET OVERVIEW 45 4.2 ASIA PACIFIC: PROTEIN A RESIN MARKET, BY COUNTRY AND END USER 46 4.3 PROTEIN A RESIN MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 47 5 MARKET OVERVIEW 48 5.1 INTRODUCTION 48 5.2 MARKET DYNAMICS 48 5.2.1 DRIVERS 49 5.2.1.1 Strong monoclonal antibody pipeline to drive demand 49 5.2.1.2 Advent of continuous bioprocessing to drive adoption 49 5.2.1.3 Increased utilization due to expansion of bispecific antibodies 50 5.2.2 RESTRAINTS 50 5.2.2.1 High manufacturing cost and pricing pressure 50 5.2.2.2 Issues associated with scaling up resin production 51 5.2.3 OPPORTUNITIES 51 5.2.3.1 Rising outsourcing to CDMOs 51 5.2.3.2 Innovative therapeutic indications 51 5.2.4 CHALLENGES 52 5.2.4.1 Limited resin reusability and fouling concerns 52 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 52 5.4 PRICING ANALYSIS 52 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER 53 5.4.2 AVERAGE SELLING PRICE TREND, BY REGION 54 5.5 VALUE CHAIN ANALYSIS 55 5.5.1 RESEARCH & DEVELOPMENT 56 5.5.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING 56 5.5.3 DISTRIBUTION AND MARKETING & SALES 56 5.5.4 AFTER-SALES SERVICES 56 5.6 SUPPLY CHAIN ANALYSIS 56 5.6.1 PROMINENT COMPANIES 57 5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES 57 5.6.3 END USERS 57 5.7 ECOSYSTEM ANALYSIS 58 5.8 INVESTMENT & FUNDING SCENARIO 59 5.9 TECHNOLOGY ANALYSIS 60 5.9.1 KEY TECHNOLOGIES 60 5.9.1.1 Recombinant protein A ligand engineering 60 5.9.1.2 Alkaline-stable ligand development 60 5.9.2 COMPLEMENTARY TECHNOLOGIES 60 5.9.2.1 Automated column packing systems 60 5.9.2.2 In-line monitoring and PAT (process analytical technology) tools 61 5.9.3 ADJACENT TECHNOLOGIES 61 5.9.3.1 Continuous chromatography systems 61 5.9.3.2 Affinity membrane technology 61 5.10 PATENT ANALYSIS 62 5.10.1 INNOVATIONS AND PATENT REGISTRATIONS 63 5.11 TRADE ANALYSIS 63 5.11.1 IMPORT DATA FOR HS CODE 3504 63 5.11.2 EXPORT DATA FOR HS CODE 3504 64 5.12 KEY CONFERENCES & EVENTS, 2025–2026 65 5.13 CASE STUDY ANALYSIS 66 5.13.1 CASE STUDY 1: STRATEGIC CAPACITY EXPANSION BY PUROLITE (ECOLAB) TO STRENGTHEN SUPPLY CHAIN RESILIENCE IN PROTEIN A RESIN BUSINESS 66 5.13.2 CASE STUDY 2: PROCESS INNOVATION BY CYTIVA TO ENHANCE REUSE CYCLES IN PROTEIN A RESINS 66 5.13.3 CASE STUDY 3: TOSOH’S SINGLE-USE STRATEGY TO TAP INTO GROWING DEMAND FOR FLEXIBLE BIOPROCESSING 66 5.14 REGULATORY ANALYSIS 67 5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67 5.14.2 REGULATORY FRAMEWORK 68 5.14.2.1 North America 68 5.14.2.1.1 US 68 5.14.2.1.2 Canada 69 5.14.2.2 Europe 69 5.14.2.2.1 UK 69 5.14.2.2.2 Germany 69 5.14.2.2.3 France 69 5.14.2.2.4 Italy 70 5.14.2.2.5 Spain 70 5.14.2.3 Asia Pacific 70 5.14.2.3.1 Japan 70 5.14.2.3.2 China 70 5.14.2.3.3 India 71 5.14.2.3.4 Australia 71 5.14.2.4 Latin America 71 5.14.2.4.1 Brazil 71 5.14.2.4.2 Mexico 72 5.14.2.5 Middle East & Africa 72 5.14.2.5.1 UAE 72 5.14.2.5.2 South Africa 72 5.15 PORTER’S FIVE FORCES ANALYSIS 73 5.15.1 THREAT OF NEW ENTRANTS 74 5.15.2 THREAT OF SUBSTITUTES 74 5.15.3 BARGAINING POWER OF SUPPLIERS 74 5.15.4 BARGAINING POWER OF BUYERS 74 5.15.5 INTENSITY OF COMPETITIVE RIVALRY 74 5.16 KEY STAKEHOLDERS & BUYING CRITERIA 75 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 75 5.16.2 BUYING CRITERIA 76 5.17 UNMET NEEDS 77 5.18 IMPACT OF 2025 US TARIFFS—PROTEIN A RESIN MARKET 77 5.18.1 INTRODUCTION 77 5.18.2 KEY TARIFF RATES 78 5.18.3 PRICE IMPACT ANALYSIS 78 5.18.4 IMPACT ON COUNTRIES/REGIONS 78 5.18.4.1 North America 78 5.18.4.1.1 US 78 5.18.4.2 Europe 79 5.18.4.3 Asia Pacific 79 5.18.5 IMPACT ON END-USE INDUSTRIES 79 5.19 IMPACT OF AI/GEN AI ON PROTEIN A RESIN MARKET 79 5.19.1 MARKET POTENTIAL OF AI/GEN AI IN PROTEIN A RESIN APPLICATIONS 79 5.19.2 AI USE CASES 80 5.19.3 KEY COMPANIES IMPLEMENTING AI/GEN AI 80 5.19.4 FUTURE OF AI/GEN AI IN PROTEIN A RESIN ECOSYSTEM 81 6 PROTEIN A RESIN MARKET, BY PRODUCT 82 6.1 INTRODUCTION 83 6.2 BULK RESINS 83 6.2.1 BULK RESINS TO HOLD LARGEST MARKET SHARE 83 6.3 PREPACKED COLUMNS 84 6.3.1 CONSISTENCY AND LOW CROSS-CONTAMINATION RISK TO SUPPORT ADOPTION 84 6.4 LAB-SCALE COLUMNS 85 6.4.1 FLEXIBILITY, LOW SAMPLE CONSUMPTION, AND HIGH THROUGHPUT TO DRIVE USAGE 85 6.5 OTHER PRODUCTS 86 7 PROTEIN A RESIN MARKET, BY SOURCE 88 7.1 INTRODUCTION 89 7.2 RECOMBINANT PROTEIN A 89 7.2.1 COST-EFFICIENCY OF RECOMBINANT PROTEINS TO DRIVE MARKET GROWTH 89 7.3 NATURAL PROTEIN A 90 7.3.1 ADVANTAGES OF RECOMBINANT PROTEIN A TO RESTRICT NATURALLY SOURCED COUNTERPARTS 90 8 PROTEIN A RESIN MARKET, BY MATRIX TYPE 92 8.1 INTRODUCTION 93 8.2 AGAROSE-BASED PROTEIN A 93 8.2.1 AGAROSE-BASED PROTEIN A TO DOMINATE MARKET 93 8.3 GLASS/SILICA-BASED PROTEIN A 94 8.3.1 LOW PH TOLERANCE OF SILICA-BASED RESINS TO LIMIT MARKET GROWTH 94 8.4 ORGANIC POLYMER-BASED PROTEIN A 95 8.4.1 INCREASING POPULARITY OF ORGANIC POLYMERS TO DRIVE MARKET GROWTH 95 9 PROTEIN A RESIN MARKET, BY APPLICATION 97 9.1 INTRODUCTION 98 9.2 MONOCLONAL ANTIBODY PURIFICATION 98 9.2.1 GROWING DEMAND, RAPID EXPANSION OF APPLICATIONS, AND INCREASING APPROVALS TO ENSURE LARGEST SHARE 98 9.3 FC-FUSION PROTEIN PURIFICATION 99 9.3.1 INNOVATION AND PATENTED PUBLICATIONS TO DRIVE MARKET 99 9.4 OTHER APPLICATIONS 100 10 PROTEIN A RESIN MARKET, BY END USER 102 10.1 INTRODUCTION 103 10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 103 10.2.1 EXTENSIVE USE IN BIOLOGICAL DRUG PRODUCTION TO ENSURE STRONG DEMAND 103 10.3 CROS & CDMOS 104 10.3.1 EXPANSION OF BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET GROWTH 104 10.4 ACADEMIC & RESEARCH INSTITUTES 105 10.4.1 INCREASING R&D IN DRUG DISCOVERY TO DRIVE USE OF PROTEIN A RESINS 105 10.5 OTHER END USERS 106 11 PROTEIN A RESIN MARKET, BY REGION 108 11.1 INTRODUCTION 109 11.2 NORTH AMERICA 109 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 110 11.2.2 US 113 11.2.2.1 Expansion in biomanufacturing and domestic capacity to drive market 113 11.2.3 CANADA 114 11.2.3.1 Policy-led capacity build and CDMO growth to drive the market 114 11.3 EUROPE 115 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 115 11.3.2 GERMANY 118 11.3.2.1 Increased capital expenditure from manufacturers to drive market 118 11.3.3 UK 119 11.3.3.1 Government policies and public-private partnerships to drive market 119 11.3.4 FRANCE 119 11.3.4.1 CDMO capacity expansion and public programs to drive market growth 119 11.3.5 ITALY 120 11.3.5.1 Increased Cap Ex from major end-user categories to grow the demand for protein A resin 120 11.3.6 SPAIN 121 11.3.6.1 Increased CDMO and CRO likely to grow demand for protein A resin 121 11.3.7 REST OF EUROPE 121 11.4 ASIA PACIFIC 122 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 123 11.4.2 JAPAN 126 11.4.2.1 CDMO capacity expansions, policy backing, and CDMO investment to propel market 126 11.4.3 CHINA 127 11.4.3.1 Robust biopharmaceutical expansion to grow demand 127 11.4.4 INDIA 127 11.4.4.1 Growth of pharma and biotech industries to drive demand for protein A resins 127 11.4.5 AUSTRALIA 128 11.4.5.1 Increasing demand for protein-based therapeutics to drive growth 128 11.4.6 SOUTH KOREA 129 11.4.6.1 Developments in biopharmaceutical sector to drive market growth 129 11.4.7 REST OF ASIA PACIFIC 130 11.5 LATIN AMERICA 131 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 131 11.5.2 BRAZIL 134 11.5.2.1 Biomanufacturing emphasis and public–private partnerships to catalyze demand 134 11.5.3 MEXICO 134 11.5.3.1 Supportive government initiatives to grow demand for protein A resin 134 11.5.4 REST OF LATIN AMERICA 135 11.6 MIDDLE EAST & AFRICA 136 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 136 11.6.2 GCC COUNTRIES 139 11.6.2.1 Favorable government policies to propel market growth 139 11.6.3 REST OF MIDDLE EAST & AFRICA 139   12 COMPETITIVE LANDSCAPE 141 12.1 INTRODUCTION 141 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 141 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PROTEIN A RESIN MARKET 141 12.3 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2024 144 12.4 MARKET SHARE ANALYSIS, 2024 144 12.4.1 MARKET RANKING OF KEY PLAYERS, 2024 146 12.5 COMPANY VALUATION & FINANCIAL METRICS 146 12.6 BRAND/PRODUCT COMPARISON 148 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 149 12.7.1 STARS 149 12.7.2 PERVASIVE PLAYERS 149 12.7.3 EMERGING LEADERS 149 12.7.4 PARTICIPANTS 149 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 151 12.7.5.1 Company footprint 151 12.7.5.2 Region footprint 152 12.7.5.3 Product footprint 152 12.7.5.4 Matrix type footprint 153 12.7.5.5 Application footprint 154 12.7.5.6 End-user footprint 154 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 155 12.8.1 PROGRESSIVE COMPANIES 155 12.8.2 RESPONSIVE COMPANIES 155 12.8.3 DYNAMIC COMPANIES 155 12.8.4 STARTING BLOCKS 155 12.8.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2024 157 12.8.5.1 Detailed list of key startups/SMEs 157 12.8.5.2 Competitive benchmarking of key startups/SMEs 158 12.9 COMPETITIVE SCENARIO 159 12.9.1 PRODUCT LAUNCHES & APPROVALS 159 12.9.2 DEALS 159 12.9.3 EXPANSIONS 160 13 COMPANY PROFILES 161 13.1 KEY PLAYERS 161 13.1.1 DANAHER 161 13.1.1.1 Business overview 161 13.1.1.2 Products offered 162 13.1.1.3 Recent developments 163 13.1.1.3.1 Product launches 163 13.1.1.3.2 Deals 163 13.1.1.3.3 Expansions 164 13.1.1.4 MnM view 164 13.1.1.4.1 Key strengths 164 13.1.1.4.2 Strategic choices 164 13.1.1.4.3 Weaknesses & competitive threats 164 13.1.2 THERMO FISHER SCIENTIFIC INC. 165 13.1.2.1 Business overview 165 13.1.2.2 Products offered 166 13.1.2.3 Recent developments 167 13.1.2.3.1 Deals 167 13.1.2.3.2 Expansions 167 13.1.2.4 MnM view 167 13.1.2.4.1 Key strengths 167 13.1.2.4.2 Strategic choices 168 13.1.2.4.3 Weaknesses & competitive threats 168 13.1.3 AGILENT TECHNOLOGIES, INC. 169 13.1.3.1 Business overview 169 13.1.3.2 Products offered 170 13.1.3.3 Recent developments 171 13.1.3.3.1 Deals 171 13.1.3.3.2 Expansions 171 13.1.3.4 MnM view 171 13.1.3.4.1 Key strengths 171 13.1.3.4.2 Strategic choices 172 13.1.3.4.3 Weaknesses & competitive threats 172 13.1.4 BIO-RAD LABORATORIES, INC 173 13.1.4.1 Business overview 173 13.1.4.2 Products offered 174 13.1.5 MERCK KGAA 175 13.1.5.1 Business overview 175 13.1.5.2 Products offered 176 13.1.5.3 Recent developments 177 13.1.5.3.1 Expansions 177 13.1.5.3.2 Other developments 178 13.1.6 REPLIGEN CORPORATION 179 13.1.6.1 Business overview 179 13.1.6.2 Products offered 180 13.1.6.3 Recent developments 181 13.1.6.3.1 Deals 181 13.1.6.4 MnM view 181 13.1.6.4.1 Right to win 181 13.1.6.4.2 Strategic choices 181 13.1.6.4.3 Weaknesses and competitive threats 181 13.1.7 TOSOH BIOSCIENCE 182 13.1.7.1 Business overview 182 13.1.7.2 Products offered 183 13.1.7.3 Recent developments 184 13.1.7.3.1 Expansions 184 13.1.8 ECOLAB INC. 185 13.1.8.1 Business overview 185 13.1.8.2 Products offered 186 13.1.8.3 Recent developments 187 13.1.8.3.1 Product launches 187 13.1.8.3.2 Deals 187 13.1.8.3.3 Expansions 187 13.1.8.4 MnM view 188 13.1.8.4.1 Key strengths 188 13.1.8.4.2 Strategic choices 188 13.1.8.4.3 Weaknesses & competitive threats 188 13.1.9 NOVASEP HOLDING 189 13.1.9.1 Business overview 189 13.1.9.2 Products offered 189 13.1.10 AVANTOR, INC. 190 13.1.10.1 Business overview 190 13.1.10.2 Products offered 191 13.1.11 OROCHEM TECHNOLOGIES, INC. 192 13.1.11.1 Business overview 192 13.1.11.2 Products offered 192 13.1.12 KANEKA CORPORATION 193 13.1.12.1 Business overview 193 13.1.12.2 Products offered 194 13.1.13 JSR CORPORATION 195 13.1.13.1 Business overview 195 13.1.13.2 Products offered 196 13.1.14 GENSCRIPT 197 13.1.14.1 Business overview 197 13.1.14.2 Products offered 198 13.2 OTHER PLAYERS 199 13.2.1 BIO-WORKS 199 13.2.2 GENO TECHNOLOGY, INC. 199 13.2.3 PROMEGA CORPORATION 200 13.2.4 SUZHOU NANOMICRO TECHNOLOGY CO., LTD. 200 13.2.5 TRANSGEN BIOTECH CO., LTD 201 13.2.6 RESYN BIOSCIENCES (PTY) LTD 201 13.2.7 BIOTOOLOMICS LTD. 202 13.2.8 CALIBRE SCIENTIFIC (PROTEIN ARK) 202 13.2.9 SUNRESIN NEW MATERIALS CO., LTD. 203 13.2.10 BEAVER 203 14 APPENDIX 204 14.1 DISCUSSION GUIDE 204 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 208 14.3 CUSTOMIZATION OPTIONS 210 14.4 RELATED REPORTS 210 14.5 AUTHOR DETAILS 211
圖表清單 List of Tables & Figures
TABLE 1 PROTEIN A RESIN MARKET: INCLUSIONS & EXCLUSIONS 23 TABLE 2 PROTEIN A RESIN MARKET: STUDY ASSUMPTIONS 39 TABLE 3 PROTEIN A RESIN MARKET: RISK ANALYSIS 39 TABLE 4 PROTEIN A RESIN MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 49 TABLE 5 KEY PARAMETERS IMPACTING PRICES FOR PROTEIN A RESIN 53 TABLE 6 AVERAGE SELLING PRICE TREND OF PROTEIN A RESIN, BY KEY PLAYER, 2022–2024 (USD) 54 TABLE 7 AVERAGE SELLING PRICE TREND OF PROTEIN A RESIN, BY REGION, 2022–2024 (USD) 55 TABLE 8 PROTEIN A RESIN MARKET: ROLE IN ECOSYSTEM 58 TABLE 9 PROTEIN A RESIN MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2022–2024 63 TABLE 10 IMPORT SCENARIO FOR HS CODE 3504, BY COUNTRY, 2020–2024 (USD THOUSAND) 64 TABLE 11 EXPORT SCENARIO FOR HS CODE 3504, BY COUNTRY, 2020–2024 (USD THOUSAND) 65 TABLE 12 PROTEIN A RESIN: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 65 TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67 TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67 TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67 TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68 TABLE 17 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANISATIONS 68 TABLE 18 PROTEIN A RESIN MARKET: PORTER’S FIVE FORCES ANALYSIS 73 TABLE 19 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF PROTEIN A RESIN, BY PRODUCT 75 TABLE 20 KEY BUYING CRITERIA OF PROTEIN A RESIN, BY END USER 76 TABLE 21 PROTEIN A RESIN MARKET: UNMET NEEDS 77 TABLE 22 US ADJUSTED RECIPROCAL TARIFF RATES, 2024 78 TABLE 23 KEY COMPANIES IMPLEMENTING AI/GEN AI IN PROTEIN A RESIN MARKET 80 TABLE 24 PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 83 TABLE 25 PROTEIN A RESIN MARKET FOR BULK RESINS, BY REGION, 2023–2030 (USD MILLION) 84 TABLE 26 PROTEIN A RESIN MARKET FOR PREPACKED COLUMNS, BY REGION, 2023–2030 (USD MILLION) 85 TABLE 27 PROTEIN A RESIN MARKET FOR LAB-SCALE COLUMNS, BY REGION, 2023–2030 (USD MILLION) 86 TABLE 28 PROTEIN A RESIN MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2030 (USD MILLION) 87 TABLE 29 PROTEIN A RESIN MARKET, BY SOURCE, 2023–2030 (USD MILLION) 89 TABLE 30 RECOMBINANT PROTEIN A MARKET, BY REGION, 2023–2030 (USD MILLION) 90 TABLE 31 NATURAL PROTEIN A MARKET, BY REGION, 2023–2030 (USD MILLION) 91 TABLE 32 PROTEIN A RESIN MARKET, BY MATRIX TYPE, 2023–2030 (USD MILLION) 93 TABLE 33 AGAROSE-BASED PROTEIN A MARKET, BY REGION, 2023–2030 (USD MILLION) 94 TABLE 34 GLASS/SILICA-BASED PROTEIN A MARKET, BY REGION, 2023–2030 (USD MILLION) 95 TABLE 35 ORGANIC POLYMER-BASED PROTEIN A MARKET, BY REGION, 2023–2030 (USD MILLION) 96 TABLE 36 PROTEIN A RESIN MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 98 TABLE 37 PROTEIN A RESIN MARKET FOR MAB PURIFICATION, BY REGION, 2023–2030 (USD MILLION) 99 TABLE 38 PROTEIN A RESIN MARKET FOR FC-FUSION PURIFICATION, BY REGION, 2023–2030 (USD MILLION) 100 TABLE 39 PROTEIN A RESIN MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 101 TABLE 40 PROTEIN A RESIN MARKET, BY END USER, 2023–2030 (USD MILLION) 103 TABLE 41 PROTEIN A RESIN MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD MILLION) 104 TABLE 42 PROTEIN A RESIN MARKET FOR CROS & CDMOS, BY REGION, 2023–2030 (USD MILLION) 105 TABLE 43 PROTEIN A RESIN MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 106 TABLE 44 PROTEIN A RESIN MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 107 TABLE 45 PROTEIN A RESIN MARKET, BY REGION, 2023–2030 (USD MILLION) 109 TABLE 46 NORTH AMERICA: KEY MACROINDICATORS 111 TABLE 47 NORTH AMERICA: PROTEIN A RESIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 48 NORTH AMERICA: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 111 TABLE 49 NORTH AMERICA: PROTEIN A RESIN MARKET, BY SOURCE, 2023–2030 (USD MILLION) 112 TABLE 50 NORTH AMERICA: PROTEIN A RESIN MARKET, BY MATRIX TYPE, 2023–2030 (USD MILLION) 112 TABLE 51 NORTH AMERICA: PROTEIN A RESIN MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 112 TABLE 52 NORTH AMERICA: PROTEIN A RESIN MARKET, BY END USER, 2023–2030 (USD MILLION) 113 TABLE 53 US: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 114 TABLE 54 CANADA: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 115 TABLE 55 EUROPE: KEY MACROINDICATORS 116 TABLE 56 EUROPE: PROTEIN A RESIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 57 EUROPE: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 116 TABLE 58 EUROPE: PROTEIN A RESIN MARKET, BY SOURCE, 2023–2030 (USD MILLION) 117 TABLE 59 EUROPE: PROTEIN A RESIN MARKET, BY MATRIX TYPE, 2023–2030 (USD MILLION) 117 TABLE 60 EUROPE: PROTEIN A RESIN MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 117 TABLE 61 EUROPE: PROTEIN A RESIN MARKET, BY END USER, 2023–2030 (USD MILLION) 118 TABLE 62 GERMANY: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 118 TABLE 63 UK: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 119 TABLE 64 FRANCE: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 120 TABLE 65 ITALY: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 120 TABLE 66 SPAIN: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 121 TABLE 67 REST OF EUROPE: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 122 TABLE 68 ASIA PACIFIC: KEY MACROINDICATORS 124 TABLE 69 ASIA PACIFIC: PROTEIN A RESIN, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 70 ASIA PACIFIC: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 124 TABLE 71 ASIA PACIFIC: PROTEIN A RESIN MARKET, BY SOURCE, 2023–2030 (USD MILLION) 125 TABLE 72 ASIA PACIFIC: PROTEIN A RESIN MARKET, BY MATRIX TYPE, 2023–2030 (USD MILLION) 125 TABLE 73 ASIA PACIFIC: PROTEIN A RESIN MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 125 TABLE 74 ASIA PACIFIC: PROTEIN A RESIN MARKET, BY END USER, 2023–2030 (USD MILLION) 126 TABLE 75 JAPAN: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 126 TABLE 76 CHINA: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 127 TABLE 77 INDIA: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 128 TABLE 78 AUSTRALIA: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 129 TABLE 79 SOUTH KOREA: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 130 TABLE 80 REST OF ASIA PACIFIC: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 131 TABLE 81 LATIN AMERICA: KEY MACROINDICATORS 131 TABLE 82 LATIN AMERICA: PROTEIN A RESIN, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 83 LATIN AMERICA: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 132 TABLE 84 LATIN AMERICA: PROTEIN A RESIN MARKET, BY SOURCE, 2023–2030 (USD MILLION) 132 TABLE 85 LATIN AMERICA: PROTEIN A RESIN MARKET, BY MATRIX TYPE, 2023–2030 (USD MILLION) 133 TABLE 86 LATIN AMERICA: PROTEIN A RESIN MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 133 TABLE 87 LATIN AMERICA: PROTEIN A RESIN MARKET, BY END USER, 2023–2030 (USD MILLION) 133 TABLE 88 BRAZIL: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 134 TABLE 89 MEXICO: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 135 TABLE 90 REST OF LATIN AMERICA: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 135 TABLE 91 MIDDLE EAST & AFRICA: KEY MACROINDICATORS 136 TABLE 92 MIDDLE EAST & AFRICA: PROTEIN A RESIN MARKET, BY REGION, 2023–2030 (USD MILLION) 137 TABLE 93 MIDDLE EAST & AFRICA: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 137 TABLE 94 MIDDLE EAST & AFRICA: PROTEIN A RESIN MARKET, BY SOURCE, 2023–2030 (USD MILLION) 137 TABLE 95 MIDDLE EAST & AFRICA: PROTEIN A RESIN MARKET, BY MATRIX TYPE, 2023–2030 (USD MILLION) 138 TABLE 96 MIDDLE EAST & AFRICA: PROTEIN A RESIN MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 138 TABLE 97 MIDDLE EAST & AFRICA: PROTEIN A RESIN MARKET, BY END USER, 2023–2030 (USD MILLION) 138 TABLE 98 GCC COUNTRIES: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 139 TABLE 99 REST OF MIDDLE EAST & AFRICA: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 140 TABLE 100 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PROTEIN A RESIN MARKET, 2022–2025 141 TABLE 101 PROTEIN A RESIN MARKET: DEGREE OF COMPETITION 145 TABLE 102 PROTEIN A RESIN MARKET: REGION FOOTPRINT 152 TABLE 103 PROTEIN A RESIN MARKET: PRODUCT FOOTPRINT 152 TABLE 104 PROTEIN A RESIN MARKET: MATRIX TYPE FOOTPRINT 153 TABLE 105 PROTEIN A RESIN MARKET: APPLICATION FOOTPRINT 154 TABLE 106 PROTEIN A RESIN MARKET: END-USER FOOTPRINT 154 TABLE 107 PROTEIN A RESIN MARKET: DETAILED LIST OF KEY STARTUPS/SMES 157 TABLE 108 PROTEIN A RESIN MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY PRODUCT AND REGION 158 TABLE 109 PROTEIN A RESIN MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025 159 TABLE 110 PROTEIN A RESIN MARKET: DEALS, JANUARY 2022–JUNE 2025 159 TABLE 111 PROTEIN A RESIN MARKET: EXPANSIONS, JANUARY 2021–JUNE 2025 160 TABLE 112 DANAHER: COMPANY OVERVIEW 161 TABLE 113 DANAHER: PRODUCTS OFFERED 162 TABLE 114 DANAHER: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025 163 TABLE 115 DANAHER: DEALS, JANUARY 2022–JULY 2025 163 TABLE 116 DANAHER: EXPANSIONS, JANUARY 2022–JULY 2025 164 TABLE 117 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 165 TABLE 118 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 166 TABLE 119 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–JULY 2025 167 TABLE 120 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–JULY 2025 167 TABLE 121 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 169 TABLE 122 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 170 TABLE 123 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022–JULY 2025 171 TABLE 124 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2022–JULY 2025 171 TABLE 125 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 173 TABLE 126 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 174 TABLE 127 MERCK KGAA: COMPANY OVERVIEW 175 TABLE 128 MERCK KGAA: PRODUCTS OFFERED 176 TABLE 129 MERCK KGAA: EXPANSIONS, JANUARY 2022–JULY 2025 177 TABLE 130 MERCK KGAA: OTHER DEVELOPMENTS, JANUARY 2022–JULY 2025 178 TABLE 131 REPLIGEN CORPORATION: COMPANY OVERVIEW 179 TABLE 132 REPLIGEN CORPORATION: PRODUCTS OFFERED 180 TABLE 133 REPLIGEN CORPORATION: DEALS, JANUARY 2022–JULY 2025 181 TABLE 134 TOSOH BIOSCIENCE: COMPANY OVERVIEW 182 TABLE 135 TOSOH BIOSCIENCE: PRODUCTS OFFERED 183 TABLE 136 TOSOH BIOSCIENCE: EXPANSIONS, JANUARY 2022–JULY 2025 184 TABLE 137 ECOLAB INC.: COMPANY OVERVIEW 185 TABLE 138 ECOLAB INC.: PRODUCTS OFFERED 186 TABLE 139 ECOLAB INC.: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025 187 TABLE 140 ECOLAB INC.: DEALS, JANUARY 2022–JULY 2025 187 TABLE 141 ECOLAB INC.: EXPANSIONS, JANUARY 2022–JULY 2025 187 TABLE 142 NOVOSEP HOLDING: COMPANY OVERVIEW 189 TABLE 143 NOVOSEP HOLDING: PRODUCTS OFFERED 189 TABLE 144 AVANTOR, INC.: COMPANY OVERVIEW 190 TABLE 145 AVANTOR, INC.: PRODUCTS OFFERED 191 TABLE 146 OROCHEM TECHNOLOGIES, INC.: COMPANY OVERVIEW 192 TABLE 147 OROCHEM TECHNOLOGIES, INC.: PRODUCTS OFFERED 192 TABLE 148 KANEKA CORPORATION: COMPANY OVERVIEW 193 TABLE 149 KANEKA CORPORATION: PRODUCTS OFFERED 194 TABLE 150 JSR CORPORATION: COMPANY OVERVIEW 195 TABLE 151 JSR CORPORATION: PRODUCTS OFFERED 196 TABLE 152 GENSCRIPT: COMPANY OVERVIEW 197 TABLE 153 GENSCRIPT: PRODUCTS OFFERED 198 TABLE 154 BIO-WORKS: COMPANY OVERVIEW 199 TABLE 155 GENO TECHNOLOGY, INC.: COMPANY OVERVIEW 199 TABLE 156 PROMEGA CORPORATION: COMPANY OVERVIEW 200 TABLE 157 SUZHOU NANOMICRO TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 200 TABLE 158 TRANSGEN BIOTECH CO., LTD: COMPANY OVERVIEW 201 TABLE 159 RESYN BIOSCIENCES (PTY) LTD: COMPANY OVERVIEW 201 TABLE 160 BIOTOOLOMICS LTD.: COMPANY OVERVIEW 202 TABLE 161 CALIBRE SCIENTIFIC (PROTEIN ARK): COMPANY OVERVIEW 202 TABLE 162 SUNRESIN NEW MATERIALS CO., LTD.: COMPANY OVERVIEW 203 TABLE 163 BEAVER: COMPANY OVERVIEW 203 FIGURE 1 PROTEIN A RESIN MARKET SEGMENTATION & REGIONAL SCOPE 22 FIGURE 2 PROTEIN A RESIN MARKET: RESEARCH DATA 25 FIGURE 3 PROTEIN A RESIN MARKET: RESEARCH DESIGN 26 FIGURE 4 PROTEIN A RESIN MARKET: KEY SECONDARY SOURCES 27 FIGURE 5 PROTEIN A RESIN MARKET: KEY DATA FROM SECONDARY SOURCES 28 FIGURE 6 PROTEIN A RESIN MARKET: KEY PRIMARY SOURCES (DEMAND AND SUPPLY SIDES) 29 FIGURE 7 PROTEIN A RESIN MARKET: KEY SUPPLY AND DEMAND-SIDE PARTICIPANTS 29 FIGURE 8 PROTEIN A RESIN MARKET: BREAKDOWN OF PRIMARY INTERVIEWS (BY COMPANY TYPE, DESIGNATION, AND REGION) 30 FIGURE 9 PROTEIN A RESIN MARKET: KEY INSIGHTS FROM PRIMARY EXPERTS 31 FIGURE 10 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 32 FIGURE 11 PROTEIN A RESIN MARKET: COMPANY REVENUE ESTIMATION 33 FIGURE 12 PROTEIN A RESIN MARKET: END-USER AND REVENUE-MAPPING-BASED MARKET SIZE ESTIMATION METHODOLOGY 34 FIGURE 13 PROTEIN A RESIN MARKET: TOP-DOWN APPROACH 35 FIGURE 14 GROWTH PROJECTIONS ON REVENUE IMPACT OF KEY MACROINDICATORS 36 FIGURE 15 PROTEIN A RESIN MARKET: DATA TRIANGULATION METHODOLOGY 38 FIGURE 16 PROTEIN A RESIN MARKET SHARE, BY PRODUCT, 2025 VS. 2030 40 FIGURE 17 PROTEIN A RESIN MARKET, BY SOURCE, 2025 VS. 2030 (USD MILLION) 41 FIGURE 18 PROTEIN A RESIN MARKET, BY MATRIX TYPE, 2025 VS. 2030 (USD MILLION) 42 FIGURE 19 PROTEIN A RESIN MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 42 FIGURE 20 PROTEIN A RESIN MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 43 FIGURE 21 PROTEIN A RESIN MARKET: GEOGRAPHIC SNAPSHOT (2024) 44 FIGURE 22 RISING ADOPTION OF PREPACKED DISPOSABLE COLUMNS TO FUEL MARKET GROWTH 45 FIGURE 23 CHINA AND JAPAN TO ACQUIRE MAJOR SHARES OF ASIA PACIFIC MARKET IN 2024 46 FIGURE 24 CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030 47 FIGURE 25 PROTEIN A RESIN MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 48 FIGURE 26 PROTEIN A RESIN MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 52 FIGURE 27 AVERAGE SELLING PRICE TREND OF PROTEIN A RESIN, BY KEY PLAYER, 2022–2024 (USD) 53 FIGURE 28 AVERAGE SELLING PRICE TREND OF PROTEIN A RESIN, BY REGION, 2022–2024 (USD) 54 FIGURE 29 PROTEIN A RESIN MARKET: VALUE CHAIN ANALYSIS 55 FIGURE 30 PROTEIN A RESIN MARKET: SUPPLY CHAIN ANALYSIS 56 FIGURE 31 PROTEIN A RESIN MARKET: ECOSYSTEM ANALYSIS 58 FIGURE 32 PROTEIN A RESIN MARKET: FUNDING AND NUMBER OF DEALS, 2019–2023 (USD MILLION) 59 FIGURE 33 NUMBER OF DEALS IN PROTEIN A RESIN MARKET, BY KEY PLAYER, 2019–2023 59 FIGURE 34 VALUE OF DEALS IN PROTEIN A RESIN MARKET, BY KEY PLAYER, 2019–2023 (USD) 60 FIGURE 35 PROTEIN A RESIN MARKET: TOP COMPANIES/APPLICANTS FOR PROTEIN A RESIN PATENTS AND NUMBER OF PATENTS GRANTED, 2015–2025 62 FIGURE 36 PROTEIN A RESIN MARKET: IMPORT SCENARIO FOR HS CODE 3504, 2020–2024 63 FIGURE 37 PROTEIN A RESIN MARKET: EXPORT SCENARIO FOR HS CODE 3504, 2020–2024 64 FIGURE 38 PROTEIN A RESIN MARKET: PORTER’S FIVE FORCES ANALYSIS 73 FIGURE 39 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR PROTEIN A RESIN, BY PRODUCT 75 FIGURE 40 KEY BUYING CRITERIA OF PROTEIN A RESIN, BY END USER 76 FIGURE 41 KEY AI USE CASES IN PROTEIN A RESIN MARKET 80 FIGURE 42 NORTH AMERICA: PROTEIN A RESIN MARKET SNAPSHOT (2024) 110 FIGURE 43 ASIA PACIFIC: PROTEIN A RESIN MARKET SNAPSHOT (2024) 123 FIGURE 44 REVENUE ANALYSIS OF KEY PLAYERS IN PROTEIN A RESIN MARKET, 2020–2024 (USD MILLION) 144 FIGURE 45 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PROTEIN A RESIN MARKET, 2024 144 FIGURE 46 MARKET RANKING OF KEY PLAYERS IN PROTEIN A RESIN MARKET, 2024 146 FIGURE 47 EV/EBITDA OF TOP THREE PLAYERS (2025) 146 FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF TOP THREE PLAYERS (2025) 147 FIGURE 49 PROTEIN A RESIN MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 148 FIGURE 50 PROTEIN A RESIN MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 150 FIGURE 51 PROTEIN A RESIN MARKET: COMPANY FOOTPRINT 151 FIGURE 52 PROTEIN A RESIN MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 156 FIGURE 53 DANAHER: COMPANY SNAPSHOT 162 FIGURE 54 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 166 FIGURE 55 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 170 FIGURE 56 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 174 FIGURE 57 MERCK KGAA: COMPANY SNAPSHOT (2024) 176 FIGURE 58 REPLIGEN CORPORATION: COMPANY SNAPSHOT (2024) 180 FIGURE 59 TOSOH BIOSCIENCE: COMPANY SNAPSHOT (2024) 183 FIGURE 60 ECOLAB INC.: COMPANY SNAPSHOT (2024) 186 FIGURE 61 AVANTOR, INC.: COMPANY SNAPSHOT (2024) 191 FIGURE 62 KANEKA CORPORATION: COMPANY SNAPSHOT (2024) 193 FIGURE 63 JSR CORPORATION: COMPANY SNAPSHOT (2024) 196 FIGURE 64 GENSCRIPT: COMPANY SNAPSHOT (2024) 198

同分類最新報告(機械與設備)

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理,提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們